Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > BUSINESS
BUSINESS
- US Court Rejects Eisai Partner’s Bid for Rehearing on Aloxi Decision
January 19, 2018
- NanoCarrier in Talks for Biz Alliance with Ceolia
January 19, 2018
- Industry Expresses Disappointment about “Expansion” of Essential Drugs; Some Looking to Real Expansion in FY2020
January 19, 2018
- Japan Units of Shire, Baxalta to Merge on Feb. 1
January 19, 2018
- Another Drug Lag “Will” Arise, Says Mitsubishi Tanabe President after JPMA Chief’s Denial
January 19, 2018
- Novartis to Transfer Rasilez to OrphanPacific in Japan
January 18, 2018
- Kissei/JCR’s Nesp Biosimilar Shows Equivalence in Japan PIII
January 18, 2018
- Life Science Institute Launches Clinical Study of IV Regenerative Medicine Product for Acute Myocardial Infarction
January 18, 2018
- Kyowa Kirin Officially Announces Launch of Japan’s 1st Rituxan Biosimilar on Jan. 18
January 18, 2018
- Mitsubishi Tanabe Grabs Add’l Indication for Novastan in China
January 17, 2018
- Toray Grants China License for Remitch OD to 3SBio
January 17, 2018
- Nichi-Iko Teams Up with 2 Philippine Companies
January 17, 2018
- Ethical Drug Sales Up 0.8% in November on Cancer Meds
January 17, 2018
- Nissui Pharmaceutical Invests 50 Million Yen in Regenerative Medicine Startup
January 16, 2018
- Repatha Auto Mini Doser Now Available in Japan
January 16, 2018
- Opdivo-Yervoy Combo Filed for RCC in Japan
January 16, 2018
- Japan’s 1st Rituxan Biosimilar to Hit Shelves as Scheduled despite Patent Suit Filed
January 16, 2018
- Janssen, NCNP Link Arms to Develop Biomarkers for Predicting Schizophrenia Risk
January 16, 2018
- JT/Torii’s JAK Inhibitor Delivers Positive PIII Data
January 15, 2018
- Takecab Most Promoted Drug for Hospital Doctors for 12 Months on End
January 15, 2018
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…